[Effects of the hormone replacement therapy on cardiovascular system, bone mass and memory in climacteric patients].
OBJECTIVE
To evaluate the effect of the hormone replacement therapy type estradiol-medroxyprogesterone and tibolona on cardiovascular system, bone mass and memory in the climacteric patients.


METHODS
From January through December 2001 at the Specialties Hospital No. 1, we included 77 consecutive climacteric patients. They were divided in 2 groups: premenopause in treatment with estradiol-medroxyprogesterone and postmenopause with tibolona. We studied cardiovascular system, the bone mass and memory. The statistical analysis was by means of t Student for difference between the groups.


RESULTS
With the estradiol-medroxyprogesterone use, the blood pressure diminished significaticantly just for systolic pressure (-10.22/-6.38 mmHg). Cholesterol and triglyceride, both diminished significantly (-43.92 mg and -58.79 mg). There is not significance for the bone mass of lumbar-spine and femoral neck (+0.68% and +0.69%) as neither in the memory test (20-22). With the tibolona use, the blood pressure was not reduced significantly (-6.93/-1.94 mmHg), with single significant reduction for cholesterol (-25.83 mg and -18.15 mg), presenting bone mass significant improvement just for femoral neck (+0.13% and +0.84%) and without improving in the memory test (17-18).


CONCLUSIONS
A diminution of lipids with the estradiol-medroxyprogesterone use, as well as reduction of the cholesterol and improvement of the bone mass with the tibolona use but without benefits in the memory test with both treatments.
Zayas Jaime
Francisco Javier
FJ
Clínica de Osteoporosis, Hospital de Especialidades número 1, Centro Médico Nacional del Noroeste, IMSS, Ciudad Obregón, Sonora. jfzayasj@prodigy.net.mx
Elizondo Alanís
Luis Jaime
LJ
Gaxiola Cueto
Marco Antonio
MA
Aragón Meras
Esperanza
E
D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D002319:Cardiovascular System / Q000187:drug effects*; D002784:Cholesterol / Q000097:blood / Q000502:physiology; D003280:Contraceptives, Oral, Synthetic / Q000494:pharmacology / Q000627:therapeutic use; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use; D020847:Estrogen Receptor Modulators / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D006801:Humans; D008525:Medroxyprogesterone / Q000494:pharmacology / Q000627:therapeutic use; D008568:Memory / Q000187:drug effects*; D008569:Memory Disorders / Q000503:physiopathology; D008875:Middle Aged; D009652:Norpregnenes / Q000494:pharmacology / Q000627:therapeutic use; D017698:Postmenopause; D016896:Treatment Outcome
D003280:Contraceptives, Oral, Synthetic; D020847:Estrogen Receptor Modulators; D009652:Norpregnenes; D004958:Estradiol; D002784:Cholesterol; C027385:tibolone; D008525:Medroxyprogesterone